Spaulding Clinical to Offer ADME Clinical Trial Services

Article

Addition solidifies commitment to delivering comprehensive solutions worldwide, company says.

Spaulding Clinical, a clinical research organization (CRO), has announced the addition of ADME (absorption, distribution, metabolism, and excretion) clinical trials to its list of services. According to the company, ADME studies are vital components of drug development, providing critical insights into the behavior of drugs within the human body.

“With the addition of ADME studies to our suite of services plus hired staff with over 60 years combined experience in conducting these trial types, Spaulding Clinical is positioned to better support our clients in making informed decisions during drug development,” said Cassandra Erato, CEO, Spaulding Clinical. “These trials play a pivotal role in understanding the behavior and fate of a drug in the body, allowing researchers to optimize dosage, assess potential drug-drug interactions, and enhance overall drug safety profiles.”

Reference: Spaulding Clinical Expands Services to Include ADME Clinical Trials. Spaulding Clinical. June 22, 2023.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.